** Hong Kong shares of CanSino Biologics Inc 6185.HK climb 2.8% to HK$29, the highest since Jan. 7; on course for third straight session of gains
** Clinical-stage vaccine company estimates its 2024 net loss narrowing to 335-385 mln yuan ($45.80-$52.63 mln) range from 1.48 bln yuan loss in 2023, with revenue amounting to 825-865 mln yuan range, as compared to 2023's 357.1 mln yuan revenue
** "During the reporting period, the group mainly focused on advancing commercialization of the meningococcal conjugate vaccines and the development of non-COVID-19 vaccine candidates" - CanSino
** Shanghai-listed stock 688185.SS rises 2.4% to 58.78 yuan, highest since Jan. 7; set for the second session of rise
** In China, the blue-chip CSI 300 Index .CSI300 gains 0.9% and the Shanghai Composite Index .SSEC adds 0.5%
** In Hong Kong, the healthcare index .HSCIH jumped 2.5% and Hang Seng Index .HSI rises 2.3%
** Last year, CanSino's Hong Kong stock rose 33.8%, while Shanghai shares fell 18.1%
($1 = 7.3148 yuan)
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。